LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 230 participants.

Also called NCT05983250

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 230 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05983250
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05983250. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-10 (actual); primary completion 2026-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Acronym
LEVEL
Intervention (Drug)
TNX-103
Intervention (Drug)
Placebo
Lead sponsor
Tenax Therapeutics, Inc. (class: industry)
Collaborator
Medpace, Inc. (class: industry)
Collaborator
Northwestern University (class: other)

Record details

Record id
cardio:ct-nct05983250
Content hash
3f7592b9fe1eedba1827b87c4c3d7d9fcd6abfa0896135c68868d3523681d777